CClinicalTrials.gg
CompletedNCT05172908Updated May 16, 2023

The Effect of Dexamethasone on Rebound Pain in Patients Receiving Ilioinguinal and Iliohypogastric Nerve Block

An interventional study of Dexamethasone and Saline in Inguinal Hernia, sponsored by Karaman Training and Research Hospital. Completed at 1 site in Turkey. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Karaman Training and Research Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Rebound pain is a newly defined phenomenon, observed within the first 24 hours after the operation. Open inguinal hernia repair is a common surgical procedure that can be associated with pain of the either acute or chronic character. A peripheral nerve block of the ilioinguinal (IIN) and iliohypogastric (IHN) nerves is a relatively well-known method for postoperative pain management. However, rebound pain after IIN/IHN block resolution may reduce its overall benefit. The primary aim is to assess whether intravenous dexamethasone reduces postoperative opioid consumption and the incidence of rebound pain in patients undergoing unilateral hernia repair in adults.

Read the detailed description

Male patients older than 18 years, of American Society of Anesthesiologists physical status I or II, and scheduled for unilateral primary hernia repair with a Lichtenstein style (open surgery with insertion of mesh) under general anesthesia will be included in the study. The patients will be randomized using a computer-generated randomization technique. After induction of general anesthesia, the patients in the dexamethasone group (Group Dex) will receive 5 mg dexamethasone in a 50 ml syringe containing normal saline. The patients in the saline group (Group S) will receive normal saline in a 50 ml syringe. Ultrasound-guided block of the ilioinguinal (IIN) and iliohypogastric (IHN) nerves will be performed on all patients included in both groups. The primary aim is to assess whether intravenous dexamethasone reduces postoperative opioid consumption and the incidence of rebound pain in patients undergoing unilateral hernia repair in adults.

02

Conditions studied

  • Inguinal Hernia

Keywords

  • Dexamethasone
  • Ilioinguinal and Iliohypogastric nerve block
  • Bupivacaine
  • Rebound Pain
03

In context

Hernia

1,096 studies on the registry are indexed under Hernia; 132 are open to participants now.

This study's enrollment of 60 is below the median of 80 across 739 interventional studies indexed under Hernia.

Browse Hernia studies →

Lead sponsor

Karaman Training and Research Hospital is the lead sponsor of 31 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • ASA I-II
  • Having signed a written informed consent form
  • Scheduled for unilateral primary hernia repair Lichtenstein style (open surgery with insertion of mesh) under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Chronic opioid use (more than one month of 60 mg of oral morphine equivalents daily)
  • Contraindications to peripheral nerve blocks including localized infection, coagulopathy, or allergy to local anesthetics
  • Stomach ulcer
  • Severe obesity (body mass index > 35 kg/m2)
  • Uncontrolled Diabetes
  • Psychiatric disorders
  • Systemic steroid use
  • Neuropathic disorder
  • Can not communicate in Turkish
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group Dexa

    After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study

    Drug: Dexamethasone

  • Sham comparator
    Group S

    After induction of general anesthesia, an ultrasound-guided block of the ilioinguinal and iliohypogastric nerve block will be performed using 20 ml 0.5% bupivacaine. 50 mL normal saline in a 50 ml syringe will be infused within 15 minutes. A multimodal analgesia regimen will be applied postoperatively. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study

    Drug: Saline

Interventions

  • DrugDexamethasone

    5 mg dexamethasone in a 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the Study participants, care providers, and data collectors will be blinded to the allocation throughout the study. Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted.

    Also known as: Global Quality of Recovery-15 score, Standard Pain Follow up

  • DrugSaline

    A 50 ml syringe containing normal saline will be infused within 15 minutes. The syringe will be prepared by a nurse outside the research team and the study participants, care providers, and data collectors will be blinded to the allocation throughout the study. Global Quality of Recovery- 15 score and standard pain follow-up scores will be noted.

    Also known as: Global Quality of Recovery-15 score, Standard Pain Follow up and Monitorization

06

What researchers measure

Primary outcomes

  1. Modified Rebound Pain Score

    Modified Rebound Pain score is described as the difference between the last recorded postanesthesia care pain score while it will be working and the highest pain score reported within the first 24 h after IIN/IHN blocks will be performed. Pain score will be calculated with Numeric Rating Scale (NRS)(0 = no pain; 10 = worst pain imaginable)

    Time frame: Postoperative 24 hours

  2. Analgesic consumption

    Postoperative total opioid consumption

    Time frame: Postoperative 24 hours

Secondary outcomes

  1. Numerical Rating Scale scores at rest and mobilization

    Pain scores (0 = no pain; 10 = worst pain imaginable) using a Numerical Rating Scale (NRS) ranging from 0 to 10.

    Time frame: Postoperative 48 hours

  2. Quality of Recovery 15 Score

    Quality of Recovery (QoR)-15 survey.Minimum value: 0, Maximum value: 150, higher scores mean better.

    Time frame: Postoperative Day 1

  3. Quality of Sleep

    Patient's perceived sleep quality will be assessed with Likert scale.Likert scale is scored from 1(very dissatisfied) to 5 (very satisfied).

    Time frame: One week after surgery

  4. Analgesic consumption

    Postoperative total opioid consumption

    Time frame: Postoperative 48 hours

  5. Adverse events

    Incidence of nausea and vomiting during postoperative 24 hour time period will be noted.

    Time frame: Postoperative 24 hour

  6. Glucose measurement

    Glucose measurement

    Time frame: Postoperative 24th hour

  7. Surgical infection

    Surgical infection

    Time frame: Postoperative 14 days

07

Study locations

1 site
  • Karaman Taining and Research Hospital
    Karaman, 70200, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05172908
Lead sponsor
Karaman Training and Research Hospital
Responsible party
Sponsor
First posted
Dec 29, 2021
Start date
Jan 6, 2022
Primary completion
Apr 15, 2023
Completion
May 15, 2023
Last update
May 16, 2023

Study contacts

Muhammet Korkusuz, MD
principal investigator · Karaman Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion